The latest innovative approaches to
the diagnosis, therapy, and prevention of cardiovascular disease will take
center stage at an upcoming international scientific symposium to be held
in Boryspil, Ukraine. Organized by the Scientific Oncological and
Cardiological Production Center "Max-Well" -- the main Ukrainian subsidiary
of US-based MaxWell Biocorporation, LLC -- the symposium will bring leading
American, Ukrainian, and European researchers together on October 24, 2008
at the spacious new Max-Well pharmaceutical fill-and-finish facility in
Boryspil.
Papers to be presented at the symposium will offer novel research into
heretofore little-understood links between latent and persistent infectious
agents (such as viruses and bacteria) and cardiovascular disease, and will
discuss promising implications for its prevention and treatment offered by
advanced biopharmaceuticals such as interferon and human growth hormone.
Speakers will represent cutting-edge medical research institutions from
Ukraine, the United States, and Western Europe, including the Academy of
Medical Sciences of Ukraine, the Amosov Institute (Ukraine), the Strazhesko
Institute (Ukraine), the Mechnikov Institute (Ukraine), the George
Washington University (USA), the University of West Virginia (USA), the
Georgetown University School of Medicine (USA), the National Institutes of
Health (USA), the Washington Hospital Center (USA), Champagne-Ardenne
University (France), and others.
Dr. Stephen Epstein, Executive Director of the Cardiovascular Research
Institute and Director of Vascular Biology Research at the MedStar Research
Institute at Washington Hospital Center, and also Clinical Professor of
Medicine at the Georgetown University School of Medicine, will give the
keynote speech at the symposium. Dr. Epstein previously served for over 30
years as Chief of the Cardiology Branch at the National Heart, Lungs, and
Blood Institute at the National Institutes of Health in Bethesda, Maryland.
Dr. Epstein is an internationally recognized authority in the field, with
over 500 publications in peer-reviewed medical journals. His current
research interests focus on understanding and treating cardiovascular
disease at the molecular level.
Ukraine is a logical location for this event: cardiovascular diseases
and disorders are the leading cause of mortality in Ukraine today, and are
responsible for the largest share of all annual deaths there, many of them
preventable.
Improving early detection, prevention, and treatment of cardiovascular
disease is a key healthcare challenge for independent Ukraine. MaxWell
Biocorporation is proud to contribute to this important goal.
About MaxWell
MaxWell Biocorporation, LLC (max-well), is a U.S.-based,
privately-held international medical and pharmaceutical company with wholly
owned subsidiaries and affiliates in the United States and Ukraine
dedicated to increasing life expectancy and improving the quality of life
of people in Ukraine and other underserved emerging healthcare markets in
the former Soviet Union. MaxWell targets oncological, cardiological,
chronic infectious and autoimmune disorders and diseases through the
development, production, and introduction into clinical practice of
sophisticated, high quality, and affordable off-patent generic
biopharmaceutical and chemopharmaceutical medicines and the latest
diagnostic and therapeutic methods. MaxWell = "Maximum Wellness."
MaxWell Biocorporation, LLC
max-well